Biotech | January 17, 2022
Green Valley receives US FDA approval for Phase II clinical trial for Parkinson’s disease
The global multi-center phase-II clinical trial will be a 36-week, multi-center, randomized, double-blind, placebo-controlled trial, followed by a 36-week open-label extension period
